Naldemedine (Symproic®): First Global Approval – new therapeutic option for sufferers of opioid-induced constipation
Author: kerrynkilkenny
I am the Content Development Manager for the Adis Business Intelligence Group. I am responsible for developing new initiatives to meet the information needs of our users in the drug development and pharmacovigilance areas. Working as part of the Product Management Team, my job is to understand what content is of value to users, establish the best way of obtaining and delivering it through our products, and then make that happen.
Ribociclib (Kisqali®): First Global Approval – next-gen cyclin-dependent kinase inhibitors a new standard of care for women with advanced breast cancer
The recent first global approval of ribociclib has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.
Fail Early, Fail Fast – and increase Likelihood of approval with biomarkers
Our partners Amplion recently published an interesting blog post on the benefits of biomarkers in informing earlier decisions in the drug development process – “fail early, fail fast” to save time and money, and increase approval success. An interesting read, check it out! Continue reading “Fail Early, Fail Fast – and increase Likelihood of approval with biomarkers”
Telotristat Ethyl (Xermelo™): First Global Approval – first and only oral drug for cancer-related diarrhoea syndrome
